Last reviewed · How we verify
NCT07072000
Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
Phase 3 trial testing standard CTV delineation in Nasopharyngeal Cancinoma (NPC) in 550 participants. Not yet recruiting.
31 July 2030
Quick facts
| Lead sponsor | Hai-Qiang Mai,MD,PhD |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 550 |
| Start date | 1 August 2025 |
| Primary completion | 31 July 2030 |
| Estimated completion | 31 July 2032 |
| Sites | 5 locations across China |
Drugs / interventions tested
- standard CTV delineation
- reduced CTV delineation
Conditions studied
- Nasopharyngeal Cancinoma (NPC) — all drugs for Nasopharyngeal Cancinoma (NPC) →
Sponsor
Hai-Qiang Mai,MD,PhD
Who can join
Adults 18 to 70, any sex, with Nasopharyngeal Cancinoma (NPC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a an open-label, non-inferiority, multicenter, randomized phase III trial aimed to explore the efficacy and safety of shrinking the anterior border of CTV2 in nasopharyngeal carcinoma patients without tumor invasion into the posterior nasal aperture.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07072000
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Nasopharyngeal Cancinoma (NPC)
Currently open trials in the same condition.
- NCT07362979 — Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal C · Phase 2 · recruiting
- NCT07496190 — Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy · Phase 2 · recruiting
- NCT07325539 — LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC · Phase 2 · recruiting
- NCT07376603 — IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features · recruiting
- NCT07311772 — Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid · Phase 3 · recruiting
Other Hai-Qiang Mai,MD,PhD trials
Trials by the same sponsor.
- NCT06912698 — Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma · Phase 3 · recruiting
- NCT03637634 — The Children and Adolescents Nasopharyngeal Carcinoma Survivor Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07072000 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hai-Qiang Mai,MD,PhD
- Last refreshed: 18 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07072000.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing